NEW YORK — SomaLogic said on Thursday that it has partnered with the US Food and Drug Administration to explore the use of large-scale protein analysis in the development of biosimilar drugs.
Under the terms of the five-year deal, SomaLogic and the FDA's Division of Applied Regulatory Science will use the company's SomaScan proteomics platform to compare changes in circulating proteins following treatment with FDA-approved biologics.